SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective PI3 kinase inhibitors for the treatment of cancer and inflammatory diseases, today announced the appointment of Clifford J. Stocks as Chief Business Officer.
